Clinical Trial Update: Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases

View source ↗

Summary

A clinical trial investigating regulation of LncRNA for Breg in patients with thymoma and autoimmune diseases has been withdrawn. The sponsor is Tianjin Medical…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Disease
• Thymoma

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Thymoma, Autoimmune Disease | Status: WITHDRAWN